Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 5/20 | 0.42 |
| ▸ | PIM1 | P11309 | 5/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.34 |
| ▸ | WEE1 | P30291 | 1/20 | 0.34 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18208948 | 0.85 | POLB (0.42) | HTR6POLBPTGS2 | |
| SCHEMBL17883350 | 0.77 | HTR6 (0.38) | HTR6TGFBR1PARP1PTGS2NOS1 | |
| SCHEMBL15307034 | 0.76 | HTR6 (0.40) | HTR6POLBPTGS2 | |
| SCHEMBL22102607 | 0.74 | NTRK1 (0.51) | NTRK1PIM1ACVR1PARP1 | |
| SCHEMBL23047161 | 0.73 | PDE10A (0.44) | HTR6PTGS2 | |
| SCHEMBL29768071 | 0.72 | IRAK4 (0.46) | PARP1PKMYT1 | |
| SCHEMBL13355648 | 0.71 | TGFBR1 (0.57) | NTRK1TGFBR1PARP1 | |
| SCHEMBL17867596 | 0.71 | NTRK1 (0.39) | NTRK1PIM1ACVR1POLBTGFBR1 | |
| SCHEMBL18122086 | 0.70 | HTR6 (0.43) | HTR6PTGS2 | |
| SCHEMBL22878396 | 0.70 | MEN1 (0.33) | NTRK1PIM1ACVR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221129-A1 | New compounds | SCD, SCD5, FASN | NTRK1 3602/4885PIM1 3219/4885ACVR1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.